Disorders of Potassium Balance (Chapter 17)
Normal potassium balance
Dietary potassium intake varies widely: less than 35 to more than 110 mmol/day in US men and women.
Despite wide intake variation, plasma potassium (K+) is tightly maintained between 3.5 and 5.0 mmol/L by homeostatic mechanisms.
In steady state, the entire daily K+ intake is excreted: ~90% in urine and ~10% in stool.
Intracellular potassium (>98% of total body K+) is predominantly in muscle; buffering of extracellular K+ by this large intracellular pool is crucial for plasma K+ regulation.
After an IV load of 0.5 mmol/kg K+-Cl−, about 41% appears in urine within 60 minutes, yet serum K+ rises by no more than ~0.6 mmol/L, illustrating rapid intracellular/extracellular buffering.
If 35 mmol K+ is added exclusively to the extracellular space of a 70-kg man, the serum K+ would be expected to rise by ~2.5 mmol/L.
During K+ depletion, skeletal muscle helps defend plasma K+ by rapid redistribution of intracellular K+ to the extracellular space; muscle K+ content and Na+/K+-ATPase activity change with K+ status (e.g., adaptations in athletes and during training).
Rapid exchange between intracellular and extracellular K+ is achieved by overlapping regulation of multiple renal and extrarenal transport pathways.
POTASSIUM TRANSPORT MECHANISMS
Na+/K+-ATPase (basolateral in most cells) accumulates K+ intracellularly against its electrochemical gradient; stoichiometry: 3 Na+ out for 2 K+ in.
Na+/K+-ATPase is a multi-subunit enzyme with tissue-specific alpha, beta, and gamma subunits; subunit composition varies by tissue and regulation.
Cardiac glycosides (digoxin, ouabain) bind extracellular sites on the Na+/K+-ATPase; binding is antagonized by extracellular K+; hypokalemia potentiates digoxin toxicity.
Four cardiac α-subunits have equivalent affinity for ouabain but differ in K+-ouabain antagonism; alpha-1 is relatively K+-insensitive within physiologic range, protecting against digoxin in the heart, while α-2/α-3 are more sensitive to inhibition.
Genetic reductions in cardiac α-1 can alter digoxin sensitivity and cardiovascular regulation.
K+ can accumulate in cells via Na+-K+-2Cl− cotransporters NKCC1 (broadly expressed) and NKCC2 (apical in TAL/macula densa).
NKCC2 is restricted to the apical membrane of the TAL and macula densa; NKCC1 is widely expressed (including muscle).
K+-Cl− cotransporters (KCC1-4) can mediate K+ influx or efflux depending on extracellular K+; these pathways typically function as efflux but can mediate influx when extracellular K+ rises.
K+ efflux is largely mediated by a large family of K+ channels: voltage-gated Kv, Ca2+-activated K+, two-pore K2P channels, and inward-rectifying Kir channels; genetic and regulatory diversity is extensive, with many subunits and splice variants.
The interplay among Na+/K+-ATPase, NKCCs, KCCs, and various K+ channels underlies both intracellular K+ handling and extracellular K+ homeostasis in kidney and excitable tissues.
FACTORS AFFECTING INTERNAL DISTRIBUTION OF POTASSIUM
A set of hormones and physiologic states acutely shift K+ distribution between intracellular and extracellular spaces (Table 17.1 summarized):
Insulin: promotes cellular K+ uptake; hypokalemia can be insulin-mediated; the effect is not renal-dependent; circulating insulin interacts with plasma K+ and glucose via separate mechanisms; SGK1 and PI3K pathways modulate Na+/K+-ATPase trafficking in skeletal muscle.
Catecholamines: beta-2 receptor stimulation increases hepatic and muscular K+ uptake (hypokalemia) via Na+/K+-ATPase activation and may involve NKCC1; alpha-adrenergic stimulation impairs buffering of IV- or exercise-induced K+ increases.
Acidosis/alkalosis: acidosis impairs cell uptake of K+; alkalosis enhances cellular K+ uptake; mechanisms involve Na+/H+ exchangers, Na+/HCO3− cotransport, and Cl−-HCO3− exchange with K+-transporters; pH shifts do not solely explain all K+-H+ exchange.
External potassium balance: lax relationships; chronic shifts (e.g., hormones) can have sustained effects on transporter/channel density.
Exercise and muscle activity: skeletal muscle (≈2500 mEq K+ stored) regulates extrarenal K+ during exercise; training increases muscle Na+/K+-ATPase content and activity, improving K+ handling and recovery after exercise.
SGK1: crucial for insulin-stimulated K+ uptake via effects on ENaC and possibly Na+/K+-ATPase trafficking; SGK1 knockout models reveal impaired K+ handling and aldosterone signaling interactions.
Angiotensin II (Ang II) and ROS/cSrc signaling play roles in distal nephron K+ handling via effects on ROMK, NCC, and WNK kinases.
Sympathetic nervous system and acid-base status have integrated effects on distal K+ handling through multiple signaling pathways and transporter regulation.
SYMPATHETIC NERVOUS SYSTEM
Table 17.2 outlines sustained effects of β- and α-adrenergic agonists and antagonists on serum K+. Key points:
Beta-adrenergic stimulation (β1/β2) generally decreases serum K+ by promoting cellular uptake of K+ (hypokalemia).
Pure β2 agonists cause hypokalemia; β-adrenergic antagonists can blunt this effect or produce opposite effects depending on context.
Alpha agonists increase serum K+ or fail to promote uptake; alpha blockade can prevent the hypokalemic response.
Net clinical implication: adrenergic tone modulates extrarenal K+ disposal, particularly during exercise and stress; understanding these signaling pathways helps explain variability in K+ handling among patients.
ACID-BASE STATUS
Classical view: alkalemia shifts K+ into cells; acidemia causes K+ release from cells.
Net K+-H+ exchange is mediated by several coupled transporters:
Na+/H+ exchangers with Na+/K+-ATPase
Na+/2HCO3− cotransport with Na+/K+-ATPase
Cl−-HCO3− exchange with K+-Cl− cotransporters
Insulin can induce translocation of Na+/K+-ATPase α2 subunit to the plasma membrane in skeletal muscle; this requires PI3K signaling and is modulated by SGK1; this effect contributes to K+ uptake during insulin action.
SGK1 also modulates ENaC surface expression and activity; interaction with Nedd4-2 ubiquitin ligase affects ENaC endocytosis and stability.
The regulation of renal K+ handling by acid-base status is integrated with aldosterone signaling and intracellular signaling networks.
RENAL POTASSIUM EXCRETION
Potassium balance is maintained by two major processes in the nephron:
Bulk reabsorption of K+ in proximal tubule and loop of Henle.
Regulated secretion of K+ in the distal nephron (connecting segment CNT and cortical collecting duct CCD).
Distal K+ secretion pathways in principal cells of CNT/CCD (Fig. 17.3):
Apical Na+ entry via ENaC generates a lumen-negative potential that drives K+ exit through apical ROMK (SK) channels.
Flow-dependent K+ secretion via BK channels on the apical membrane.
Chloride-dependent, electroneutral K+ secretion likely via K+-Cl− cotransporters.
Basolateral Na+/K+-ATPase provides the driving force for Na+ entry and K+ exit at the apical membrane.
Aldosterone effects (Fig. 17.4 and related text): increases ENaC density and activity (alpha-ENaC transcription; subunit trafficking to apical membrane; SGK1 induction; Nedd4-2 repression); thereby increasing the driving force for distal K+ secretion.
ENaC trafficking and regulation: proteolytic cleavage of ENaC subunits (CAP1/prostasin, CAP2, CAP3) by channel-activating proteases enhances ENaC activity; SGK1 and aldosterone coordinate ENaC surface expression with protease activity.
ROMK trafficking: regulated by tyrosine phosphorylation; intrarenal tyrosine kinases (c-Src, c-Yes) and ROS signaling are affected by dietary K+; Ang II can inhibit ROMK via ROS and c-Src signaling, particularly during low-K+ intake.
The distal nephron also reabsorbs K+ under K+-restricted conditions via H+/K+-ATPase in the outer medullary collecting duct (OMCD).
Integrated distal regulation (Aldosterone Paradox): under low Na+ intake with high aldosterone, Na+ reabsorption increases but K+ secretion is not proportionally increased due to electroneutral Na+-Cl− transport in CCD, ENaC-independent K+ secretion, and differential signaling by Aldosterone, Ang II, and dietary K+.
Electronegative Na+-Cl− transport in CCD (NCC-dependent) and ENaC-independent K+ secretion help decouple Na+ and K+ handling in distal nephron.
Distal potassium handling is highly sensitive to dietary K+ intake and to signaling via WNK kinases, SGK1, and c-src. WNK1-S acts as a molecular switch to regulate ROMK endocytosis and ROMK-mediated secretion, adapting to dietary K+ status.
TRPV4 (flow sensor) increases intracellular Ca2+ to activate BK channels, enhancing flow-dependent K+ secretion; aldosterone upregulates TRPV4 with high-K+ diets.
DCT NCC activity is modulated by Ang II via WNK-SPAK and phosphorylation; high-K+ diets suppress Ang II, leading to NCC inactivation and promoting K+ secretion; low-K+ diets activate NCC via Ang II and SPAK/WNK signaling to preserve Na+ delivery downstream.
CaSR in CCD may regulate K+ secretion by inhibiting ROMK endocytosis, thus limiting kaliuresis when extracellular Ca2+ is altered.
INTEGRATED REGULATION OF DISTAL SODIUM ABSORPTION AND POTASSIUM SECRETION (ALDOSTERONE PARADOX)
Under low Na+ intake and high aldosterone, ENaC-driven luminal potential would promote K+ secretion, yet Na+ reabsorption via electroneutral CCD transport and ENaC-independent K+ secretion prevents excessive kaliuresis.
Key supporting mechanisms:
Electronegative Na+-Cl− transport in CCD via SLC4A8 (Cl−/HCO3− exchanger) and SLC26A4 (Cl−/HCO3− exchanger) reduces direct impact on K+ secretion.
NCC activity in the DCT is a major control point for Na+ delivery downstream; its activity is modulated by Ang II and dietary K+ to influence distal Na+ delivery and K+ secretion.
WNK kinases (WNK1-L, WNK1-S, WNK4) integrate dietary potassium and Na+ transport through NCC and ROMK regulation; KS-WNK1 (kidney-specific WNK1 isoform) participates in this integration by modulating WNK1-L effects on NCC and ROMK.
SGK1 increases ENaC surface expression, collaborating with CAP proteases and Nedd4-2 to control ENaC trafficking and activity.
Figure 17.6 summarizes how aldosterone, Ang II, and potassium intake create networked pathways that govern NCC, ROMK, and ENaC to balance Na+ and K+ handling in the distal nephron.
CONTROL OF POTASSIUM SECRETION: EFFECT OF POTASSIUM INTAKE
Dietary K+ intake rapidly modulates distal secretory capacity:
High K+ intake increases SK (ROMK) density and apical ROMK expression, enhances ENaC activity slightly, and increases BK channel trafficking; these changes occur within hours with little change in circulating aldosterone.
TRPV4 channels are upregulated by aldosterone on high-K+ diets, increasing flow-induced Ca2+ entry and BK activation.
WNK signaling adjusts ROMK and NCC activity to optimize K+ secretion or retention depending on K+ intake.
The key regulators are WNK1-S/ L balance, SGK1, c-src, and aldosterone signaling; together they coordinate the distal nephron’s response to dietary K+.
REGULATION OF RENAL RENIN AND ADRENAL ALDOSTERONE
The RAAS axis is central to K+ homeostasis:
Renin release from juxtaglomerular cells is stimulated by macula densa signaling (decreased luminal Cl− via NKCC2), reduced renal perfusion pressure, and renal sympathetic activity; COX-2–derived prostaglandins from macula densa recruit renin in salt restriction and diuretic use.
Aldosterone release from the adrenal cortex responds to Ang II and to extracellular K+ as independent, synergistic stimuli; K+ directly depolarizes glomerulosa cells (via Cav3.2 Ca2+ channels) and enhances aldosterone synthesis; Ang II and K+ signaling synergize to increase aldosterone production.
Ang II also modulates NCC activity via WNK-SPAK signaling and can inhibit ROMK via c-Src–dependent pathways; dietary K+ modulates these signaling cascades to coordinate Na+ delivery and K+ secretion.
Somatic adrenal mutations (e.g., KCNJ5, CACNA1D) and GGTP-like enhancers of aldosterone production (APCCs) contribute to autonomous aldosterone secretion and primary aldosteronism (PA).
Somatic mutations in aldosterone-driver genes include KCNJ5 (GIRK4) and CACNA1D; APAs with KCNJ5 mutations show higher aldosterone, lateralization indices, and can be cured by adrenalectomy.
FH-I (glucocorticoid-remediable hyperaldosteronism) is caused by a chimeric CYP11B1-CYP11B2 gene, under ACTH control; germline mutations predispose patients to PA and associated stroke risk; genetic testing is increasingly used for diagnosis.
APCCs (aldosterone-producing cell clusters) exist in non-neoplastic adrenal tissue near APAs and may represent precursors to APAs; they can harbor aldosterone-driver mutations and contribute to renin-independent PA. Glucocorticoids may regulate cortisol and hybrid steroids in PA variants.
Diagnostic pathway for PA often uses PAC:PRA ratio, confirmatory suppression testing, imaging (CT), and adrenal venous sampling (AVS) to distinguish APA from bilateral hyperplasia and FH forms.
Treatments for PA include surgical adrenalectomy for unilateral disease (APA/PAH) and mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone) for bilateral disease or when surgery is not appropriate.
URINARY INDICES OF POTASSIUM EXCRETION
TTKG (transtubular potassium gradient) is used to assess distal tubular K+ secretion:
where UK = urine K+, PK = plasma K+, UOSM = urine osmolality, POSM = plasma osmolality.Expected values: TTKG < 3–4 in hypokalemia; TTKG > 6–7 in hyperkalemia. Interpret with caution because renal water handling (UU) and distal flow impact the ratio.
Water reabsorption in CCD/ medullary collecting duct influences final urine K+ and TTKG; distal urea reabsorption may affect K+ handling but does not reliably predict TTKG changes.
Urinary anion gap measurement provides a rough index of NH4+ excretion and acid-base responsiveness; K+ handling responses to acidosis/alkalosis can be inferred from this alongside TTKG.
In hypokalemia, a TTKG < 2–3 supports redistributive causes; a TTKG > 4 supports renal K+ wasting.
Urine K+-to-creatinine ratio is a practical alternative in hypokalemia for distinguishing dietary/redistribution from renal K+ loss; a ratio < 13 mEq/g creatinine suggests non-renal causes, whereas higher values indicate renal wasting.
CONSEQUENCES OF HYPOKALEMIA AND HYPERKALEMIA
Hypokalemia (low serum K+) effects:
Cardiac: predisposes to ventricular and atrial arrhythmias; perioperative risk higher when K+ < 3.5 mmol/L; ECG changes include flat or broad T waves, ST depression, QT prolongation; risk increases when K+ < 2.7 mmol/L.
HERG/IKr downregulation: reduced IKr leads to delayed repolarization and predisposes to torsades de pointes; hypokalemia promotes degradation of HERG channel and IKr.
Skeletal muscle: hypokalemia causes weakness and possible paralysis due to hyperpolarization; historically linked to diaphragmatic weakness in DKA treatment and hypokalemic myopathy.
Renal: may promote nephropathy and nephrocalcinosis with certain Gitelman/Bartter forms; can worsen hypertension, vascular calcification, and metabolic syndrome due to downstream signaling.
Hyperkalemia (high serum K+) effects:
Cardiac: depolarizes myocytes, increases excitability, then may cause conduction abnormalities; can lead to sine-wave rhythm and arrest with severe hyperkalemia; ECG patterns progress from tall T waves to widened QRS, loss of P waves, to sine wave in severe cases.
Nerve/nerve conduction: hyperkalemia can alter conduction and cause paralysis in severe cases; risk of arrhythmias is higher with rapid K+ rise.
NH4+ handling: hyperkalemia impairs ammoniagenesis and renal acid excretion, contributing to metabolic acidosis in certain settings (e.g., hyporeninemic hypoaldosteronism).
HYPERKALEMIA: CAUSES AND MANAGEMENT
Etiologies include: reduced renal excretion (hypoaldosteronism, CKD), RAAS inhibitors (ACE inhibitors, ARBs, aliskiren), drugs that impair ENaC or aldosterone signaling (TMP-SMX, amiloride, triamterene, spironolactone, eplerenone, nafamostat), NSAIDs/COX-2 inhibitors, cyclosporine, tacrolimus, heparin, and conditions causing acidosis or tissue breakdown (rhabdomyolysis, tumor lysis).
Medication-related hyperkalemia is common with RAAS blockade; risk factors include CKD, diabetes, elderly, and concurrent NSAIDs or K+-sparing therapies.
Emergency management (acute hyperkalemia): hospitalization and continuous ECG monitoring when K+ ≥ 6.5–7.0 mmol/L or with ECG changes; treat promptly to reduce mortality risk.
Acute management steps:
1) Stabilize the myocardium with intravenous calcium (calcium chloride or calcium gluconate; typical initial dose 10 mL of 10% calcium gluconate or 3–4 mL of calcium chloride given IV over 2–3 minutes; onset 1–3 minutes; duration 30–60 minutes).
2) Redistribute K+ from extracellular to intracellular space: insulin with glucose (e.g., 10 U regular insulin IV with 50 mL of 50% glucose; monitor for hypoglycemia; alternative regimens include insulin infusion 60 minutes with dextrose), sodium bicarbonate (only in acidemic or specific contexts; evidence of acute K+ lowering is mixed), beta-2 agonists (albuterol 0.5 mg IV in 100 mL dextrose if IV form; or nebulized 10–20 mg; onset ~30 minutes; peak ~90 minutes; duration 2–6 hours).
3) Epinephrine can be considered in some settings as a redistribution strategy.
4) Remove K+ from the body: diuretics (loop or thiazide-like) if there is residual renal function; dialysis (hemodialysis or peritoneal dialysis) for rapid removal; potassium-binding resins (sodium polystyrene sulfonate, SPS) but with significant safety concerns regarding intestinal necrosis, especially with sorbitol-containing preparations; newer binders patiromer and ZS-9 (calcium- or sodium-based binders) offer alternatives; dosing and interactions must be carefully managed.
5) Avoid bicarbonate alone as a primary therapy for rapid K+ lowering in most acute settings; isotonic bicarbonate may aid in some cases with acidosis or volume expansion but has limited acute K+ lowering effect and can cause volume overload or calcium shifts.Dialysis-specific considerations:
In severe hyperkalemia or when rapid correction is required, hemodialysis is preferred; dialysate potassium concentration is crucial: 0 or 1 mEq/L baths provide rapid K+ removal but risk arrhythmias and hemodyalitic instability; consider potassium profiling to maintain a safer, gradual decline and reduce reperfusion-related arrhythmias.
Glucose-containing dialysates influence insulin and K+ distribution; glucose-free dialysates may remove more K+; the net effect depends on insulin status and dialysate composition.
Cation-exchange resins:
SPS exchanges Na+ for K+ in the colon; efficacy is relatively slow; often used as temporizing measure if dialysis is not immediately available; risk of intestinal necrosis substantial, especially with sorbitol-containing formulations; FDA warnings prohibit routine concomitant sorbitol use; non-sorbitol SPS formulations exist but may still carry risk; dosing typically 15–30 g every 4–6 hours, with rectal enemas available for non-oral administration.
Newer agents: patiromer (calcium-sorbant for K+; interactions with ciprofloxacin, thyroid hormone, and metformin require timing adjustments) and sodium zirconium cyclosilicate (ZS-9), an inorganic nonabsorbable compound that exchanges Na+ and H+ for K+ and NH4+; HARMONIZE trial showed dose-dependent reductions in serum K+ with ZS-9; adverse events include edema and potential hypokalemia.
Other adjuncts:
ACE inhibitors or ARBs, MR antagonists, or other RAAS-modulating therapies should be managed to minimize hyperkalemia risk; guidelines emphasize monitoring and balancing cardiovascular benefits with hyperkalemia risk; in CKD, combination therapy requires close monitoring and possible dose adjustments.
Avoid rapid, repeated potassium repletion; ensure reassessment of the K+ load and renal function after treatment; correct underlying disturbances.
Special considerations and notes:
Bicarbonate has limited acute efficacy for hyperkalemia and should not be used as a primary therapy in many acute settings; in CKD with acidosis, bicarbonate can lower K+ over several hours, but water balance and electrolyte shifts must be monitored.
Beta-blockers generally increase the risk of hyperkalemia via reduced renin and aldosterone production.
In hyperkalemia with renal failure, consider multiple therapeutic modalities in combination (redistribution plus removal) to safely manage K+.
HYPERKALEMIA: CAUSES BEYOND RAAS BLOCKADE AND DRUGS
Hyporeninemic hypoaldosteronism: a common predisposing factor for hyperkalemia in diabetics, older adults, and CKD; characterized by low PRA and aldosterone, often with acidosis and impaired ammoniagenesis; volume status and ANP levels contribute to the phenotype; management includes addressing RAAS and potential diuretics to modify Na+ load and K+ excretion.
Hypoaldosteronism: primary or secondary; primary forms include adrenal diseases (e.g., Addison’s, 11β-HSD-2 deficiency), congenital adrenal disorders; secondary forms include aging, illness, or renal disease; drug-induced hypoaldosteronism can occur with heparin, ACE inhibitors, ARBs, NSAIDs, and certain antibiotics.
Syndromes of apparent mineralocorticoid excess (AME): 11β-HSD-2 deficiency (loss of cortisol inactivation to cortisone in mineralocorticoid target tissues) leads to unopposed cortisol at MR, causing hypertension and hypokalemia; licorice (glycyrrhetinic acid) inhibits 11β-HSD-2, promoting hyperkalemia and mineralocorticoid effects; other drugs (itraconazole, posaconazole) can also inhibit 11β-HSD-2; 11β-HSD-2 mutations or dysfunction can lead to persistent mineralocorticoid-like effects.
Primary hyperaldosteronism (PA): aldosterone excess leads to potassium wasting; PA can be due to unilateral aldosterone-producing adenoma (APA), bilateral hyperplasia (PAH), or idiopathic hyperaldosteronism (IHA); somatic mutations in aldosterone-driver genes (KCNJ5, CACNA1D, ATP1A1, ATP2B3, CTNNB1) contribute to hyperaldosteronism; APA mutations correlate with higher aldosterone and lateralization indices; treatment includes surgery or MR antagonists; diagnosis involves PAC:PRA ratio, suppression testing, imaging, AVS.
Pseudohypoaldosteronism type II (Gordon syndrome, FHHt): autosomal dominant with hypertension, hyperkalemia, metabolic acidosis, suppressed PRA and aldosterone, hypercalciuria; caused by mutations in WNK kinases or trafficking regulators (WNK1, WNK4, KLHL3, CUL3); thiazide diuretics often correct the phenotype by inhibiting NCC.
Bartter and Gitelman syndromes (hereditary hypokalemic alkalosis): Bartter syndrome (NKCC2, ROMK, Barttin, CLC-NKB) mimics loop diuretic effects with hypercalciuria and variable hypomagnesemia; Gitelman syndrome (NCC/SLC12A3 mutations) features hypocalciuria and hypomagnesemia; podiatric differences and management differ; genetic panel testing common due to heterogeneity.
Thyrotoxic periodic paralysis (TPP): hypokalemia with weakness in the context of hyperthyroidism; mutations in KCNJ18 (Kir2.6) and other Kir channel genes implicated; insulin and β-adrenergic signaling contribute to shifting of K+ into cells; KL channel dysfunction and Na+/K+-ATPase activity implicated; treatment includes beta-blockade (propranolol) to rapidly correct symptoms and careful K+ supplementation due to rebound risk.
Other pharmacologic causes: 11β-HSD-2 inhibitors (licorice, itraconazole, posaconazole) can promote hyperkalemia; certain drugs can alter ENaC or aldosterone signaling to promote potassium retention or excretion depending on context.
Non-renal losses, GI losses, or diuretic therapies can contribute to longstanding hypokalemia or hyperkalemia depending on the net balance of losses and renal handling; management should address underlying factors (volume status, Na+ delivery, and renal function).
HYPOKALEMIA: CAUSES, DIAGNOSIS, AND MANAGEMENT
Common causes include gastrointestinal losses, diuretic use (especially thiazides), hypomagnesemia, genetic disorders (Gitelman, Bartter), hyporeninemic hypoaldosteronism, renal tubular acidosis (RTA), and redistribution from insulin, catecholamines, or alkalosis.
Epidemiology: Hypokalemia is common in hospitalized patients; prevalence varies with definition (K+<3.6 mmol/L or <3.4 mmol/L); incidence is high with thiazide diuretics; hypokalemia increases in-hospital mortality risk.
Redistributive causes (transcellular shifts) include insulin excess, beta-2 adrenergic stimulation, thyrotoxic periodic paralysis, and severe hypophosphatemia; head injury and alcohol withdrawal can also induce redistribution.
Spurious hypokalemia may occur due to delayed sample analysis or sample handling; leukocytosis, thrombocytosis, or erythrocytosis can cause pseudohypokalemia.
Diagnosis and workup approach (Fig. 17.11): Start with history, physical exam, and basic labs; determine clinical emergency signs; if persistent hypokalemia despite treatment, pursue a structured workup including urinary potassium excretion (TTKG and urine K+/creatinine ratio), urinary Mg2+ and Ca2+, and RAAS axis tests (renin and aldosterone).
Hypokalemia treatment strategy (Key principles):
Correct total body K+ deficit while avoiding rebound hyperkalemia; monitor serum K+ closely during replacement.
In hypomagnesemic patients, correct Mg2+ prior to K+ repletion as Mg2+ deficiency impairs K+ repletion and may promote ongoing K+ loss.
If redistribution is the primary cause, correct the underlying trigger and carefully replete K+ to avoid overshoot.
Dietary approaches: increase intake of potassium-rich foods as first-line; box Box 17.1 lists high-K+ foods; oral supplementation is often necessary; potassium chloride is the default salt for replacement; potassium phosphate or potassium bicarbonate may be used in specific contexts (phosphate deficiency, metabolic acidosis).
For severe hypokalemia with life-threatening symptoms, initiate intravenous K+-Cl− replacement (often 20–40 mmol K+ per liter of fluid; careful to not exceed safe infusion rates and monitor for hyperkalemia).
Target serum K+ goals vary by comorbidity; some guidelines aim for 4.0–4.5 mmol/L in high-risk patients; in diabetes and renal disease, a careful target around 4.0 mmol/L is common.
Hypokalemia management in specific conditions:
Bartter and Gitelman syndromes require long-term therapy with salt intake, magnesium supplementation (for GS), and potassium supplementation; monitoring of calcium and magnesium is essential.
Hypokalemic paralysis (hypokalemic periodic paralysis) requires rapid K+ repletion with caution due to potential rebound hyperkalemia and the underlying channelopathies; concurrent management of thyroid status (in TPP) is critical.
Hypokalemia with acidosis (RTA) requires bicarbonate replacement and careful potassium management; Fanconi syndrome or proximal tubulopathy may require addressing other electrolyte disturbances.
HYPERKALEMIA: DIAGNOSIS, CONSEQUENCES, AND MANAGEMENT (RECAP)
Definition: hyperkalemia defined as K+ ≥ 5.5 mmol/L (some sources use 5.0–5.4 mmol/L).
Clinical significance: associated with mortality in hospitalized patients, particularly with CKD and cardiovascular disease; risk increases with rapid rises in K+ and with concurrent acidosis or calcium abnormalities.
Diagnostic workup: determine underlying cause (hypoaldosteronism, renal failure, RAAS inhibitors, NSAIDs, diuretics, tissue breakdown, acidosis, and iatrogenic causes). Use urinary indices (TTKG, urine Na+, urinary anion gap) to assess distal potassium handling and aldosterone responsiveness.
Management framework (acute): three-part approach (cardiac stabilization, redistribution, then removal of K+):
Immediate stabilization with IV calcium (calcium gluconate or chloride).
Redistribution: insulin with glucose; beta-2 agonists; bicarbonate in select cases; epinephrine as an adjunct in some settings.
Removal: diuretics if renal function sufficient; dialysis for rapid clearance; cation-exchange resins (SPS); newer binders patiromer and ZS-9; consider RAAS suppression adjustments with careful monitoring to avoid rebound hyperkalemia.
Special considerations: avoid rapid shifts that cause hemodynamic instability; monitor for rebound hyperkalemia after dialysis; adjust dialysate K+ carefully (profiling for severe hyperkalemia); evaluate for underlying etiology to prevent recurrence.
HYPERKALEMIA: THERAPIES IN DETAIL
Calcium: administer calcium to stabilize myocardium; dose examples and cautions (avoid overcorrection; be careful in digoxin-treated patients).
Insulin and glucose: standard regimen is 10 units regular insulin IV with 25 g glucose; onset 10–20 minutes; peak 30–60 minutes; duration 4–6 hours; monitor for hypoglycemia; in hyperglycemic patients, insulin may be given without additional glucose and with glucose monitoring; consider co-administration with beta-2 agonists for additive effect.
Beta-2 agonists: inhaled (nebulized) albuterol or terbutaline can lower K+ by ~0.5–1.0 mmol/L; onset within 30–60 minutes; additive with insulin; monitor tachycardia and glucose changes.
Sodium bicarbonate: mixed evidence for acute K+ lowering; may help in acidemic patients or in hyperkalemia with acidosis; not a universal first-line therapy in the absence of acidosis.
Dialysis/dialysis strategies: standard hemodialysis with a higher or lower K+ dialysate depending on clinical scenario; consider potassium profiling; manage potential rebound post-dialysis.
Cation-exchange resins: SPS with sorbitol has significant risk of intestinal necrosis; FDA has warned against routine use with sorbitol; non-sorbitol formulations exist; efficacy is limited in the first 24 hours and may be insufficient for rapid correction in severe hyperkalemia; use as temporizing measure if dialysis is not immediately available.
Patiromer and ZS-9: newer oral potassium binders with favorable safety profiles; potential drug interactions; used for chronic management and to facilitate RAAS blockade; short-term and long-term data emphasize safety and efficacy; monitor for hypomagnesemia with patiromer therapy.
NONRENAL POTASSIUM LOSS AND OTHER CAUSES OF HYPERKALEMIA
Hyporeninemic hypoaldosteronism: common in diabetics and CKD; acidosis and decreased NH4+ excretion contribute to hyperkalemia; volume status and ANP levels influence RAAS activity.
Syndromes of apparent mineralocorticoid excess (AME): 11β-HSD-2 defects or inhibition (licorice, itraconazole, posaconazole) cause cortisol-driven MR activation; results in hypertension and hypokalemia; diagnostic testing includes urinary cortisol/cortisone ratios.
Pseudohypoaldosteronism type I and II (PHA-I and PHA-II): genetic disorders affecting ENaC or WNK pathways; PHA-I (autosomal dominant or recessive) causes salt-wasting and hyperkalemia in infancy; PHA-II (Gordon syndrome) causes hypertension and hyperkalemia treated with thiazide diuretics.
Adrenal diseases and medications (heparin, ciclosporin, tacrolimus) can suppress aldosterone production or otherwise alter renal K+ handling, contributing to hyperkalemia.
Acute and chronic conditions (tumor lysis syndrome, rhabdomyolysis, acidosis) can cause hyperkalemia via extracellular K+ release from damaged cells.
CLINICAL APPROACH TO hypokalemia (summary diagnostic pathway)
Stepwise approach (Fig. 17.11):
Evaluate for emergency signs and symptoms; correct immediately if needed.
Obtain history of diuretics, laxatives, licorice intake, antibiotics, herbal meds, GI losses, vomiting, diarrhea, and surreptitious vomiting.
Check baseline labs: electrolytes, Mg2+, Ca2+, renin, aldosterone, bicarbonate status, pH, GFR, and urinary indices (urine K+, Cl−, Mg2+; TTKG; urinary anion gap).
Use TTKG and K+/creatinine ratio to discern redistribution vs renal potassium loss.
If hypokalemia is persistent or severe, search for GS, BS, Liddle syndrome, AME, CAH, and other hereditary conditions; utilize genetic testing as indicated.
Treat underlying cause; correct K+ deficit with appropriate strategies; address coexisting Mg2+ deficiency; monitor for rebound hyperkalemia.
POTASSIUM REPLACEMENT AND NUTRITIONAL MANAGEMENT
Potassium replacement strategies (hypokalemia):
Oral replacement is preferred when feasible; dietary K+ (K+-rich foods) is a primary method; Box 17.1 lists high-K+ foods.
If dietary intake is insufficient or rapid correction is required, use potassium chloride as default; potassium phosphate or potassium bicarbonate in selected cases (e.g., phosphate deficit, metabolic acidosis).
For significant K+ deficits, oral replacement can rapidly raise K+ by ~0.5–1.0 mmol/L within hours; larger deficits require multi-day repletion.
Intravenous K+ replacement is reserved for life-threatening hypokalemia or when oral intake is not possible; rates must be carefully controlled (typically 10–20 mmol/hour with careful monitoring; higher rates used only in life-threatening situations with continuous ECG monitoring).
In coexisting hypomagnesemia, treat Mg2+ deficiency first or concurrently; Mg2+ repletion often improves response to potassium supplementation.
Practical considerations: avoid rapid corrections that could cause volume overload or electrolyte imbalances; monitor osmolar status and pH; consider coexisting acid-base disorders; adjust therapy for CKD, liver disease, heart failure, or other comorbidities.
SUMMARY OF KEY EQUATIONS AND NUMBERS TO REMEMBER
Plasma potassium range for normal homeostasis:
Daily potassium handling and buffering: roughly
Intracellular K+ reservoir is vast; most body K+ is intracellular, especially in muscle (approx. >98 ext{%} of total body K+).
Na+/K+-ATPase stoichiometry: (energy consuming).
TTKG for distal potassium secretion:
Expected values: Hypokalemia: <3–4; Hyperkalemia: >6–7.Potassium replacement pharmacokinetics (typical example): IV insulin 10 U with 25 g glucose; onset 10–20 min; peak 30–60 min; duration 4–6 h; serum K+ fall ~0.5–1.2 mmol/L.
Calcium for hyperkalemia (emergency): 10 mL of 10% calcium gluconate (or equivalent calcium chloride) IV, onset within 1–3 minutes; duration 30–60 minutes.
Dialysate potassium profiling: consider starting with higher K+ bath for rapid lowering, then stepwise reduction to avoid rebound and arrhythmias.
New potassium binders: patiromer (binds K+ in exchange for Ca2+); ZS-9 (sodium and hydrogen exchange for K+ and NH4+); dosing and drug interactions must be managed; early data show efficacy in reducing serum K+ with a relatively favorable safety profile compared with SPS.
ADDITIONAL CLINICAL NOTES
The chapter emphasizes mechanistic understanding of potassium homeostasis to enable mechanistic diagnosis and targeted therapy for potassium disorders.
Advances in molecular biology and pharmacology (e.g., WNK kinases, SGK1, CAP proteases, CaSR, and TRPV4) provide insight into the pathophysiology of inherited and acquired disorders and inform potential therapeutic approaches.
The treatment of potassium disorders requires careful consideration of comorbidities (CKD, heart failure, diabetes), concomitant medications, dietary intake, and the dynamic balance between redistribution and excretion.
Ethical and practical implications include ensuring safe use of high-alert medications, avoiding potentially fatal treatment-related adverse events (e.g., SPS-associated intestinal necrosis), and balancing the benefits of RAAS blockade with the risk of hyperkalemia through careful monitoring and alternative strategies when needed.
KEY TAKEAWAYS
Potassium homeostasis is a tightly regulated, multi-organ process involving intracellular buffering, renal secretion, hormonal control (aldosterone, Ang II, insulin), and dietary intake.
Distal nephron (CNT/CCD) is the principal site of regulated K+ secretion; ENaC-driven lumen-negative potential drives ROMK- and BK-mediated secretion; amiloride-sensitive ENaC density is modulated by aldosterone via SGK1 and Nedd4-2 interactions.
The aldosterone paradox describes how Na+ and K+ homeostasis can be independently regulated in the distal nephron under different dietary potassium and sodium conditions.
Hypokalemia and hyperkalemia carry significant cardiovascular and neuromuscular risks; management requires rapid stabilization, redistribution, and definitive removal or correction of the underlying cause, along with addressing dietary and pharmacologic contributors.
New therapeutic agents (patiromer, ZS-9) offer alternative strategies for chronic hyperkalemia management and enabling continued RAAS blockade in patients at risk for hyperkalemia; SPS remains an option but carries serious safety concerns that limit its use in acute settings.
Note: The above notes summarize and organize the content from the provided transcript of Chapter 17: Disorders of Potassium Balance. Numerical values, formulas, and mechanistic details are included where explicitly described in the text. For visual figures and exact data points, please refer to the figures and tables cited in the transcript (e.g., Figs. 17.1–17.6, 17.7, 17.9–17.15, Tables 17.1–17.2, Box 17.1).